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Abstract
Purpose Matrix metalloproteinases (MMPs), a group of
more than 20 zinc-containing endopeptidases, are upregu-
lated in many diseases, but several attempts to use radio-
labelled MMP inhibitors for imaging tumours have proved
unsuccessful in mouse models, possibly due to the limited
specificity of these agents or their unfavourable pharmaco-
kinetic profiles. In principle, radiolabelled monoclonal
antibodies could be considered for the selective targeting
and imaging of individual MMPs.
Methods We cloned, produced and characterized high-
affinity monoclonal antibodies specific to murine MMP-
1A, MMP-2 and MMP-3 in SIP (small immunoprotein)
miniantibody format using biochemical and immunochem-
ical methods. We also performed comparative biodistribu-
tion analysis of their tumour-targeting properties at three
time points (3 h, 24 h, 48 h) in mice bearing subcutaneous
F9 tumours using radioiodinated protein preparations. The
clinical stage L19 antibody, specific to the alternatively
spliced EDB domain of fibronectin, was used as reference
tumour-targeting agent for in vivo studies.
Results All anti-MMP antibodies and SIP(L19) strongly
stained sections of F9 tumours when assessed by immuno-
fluorescence methods. In biodistribution experiments, SIP
(SP3), specific to MMP-3, selectively accumulated at the
tumour site 24 and 48 h after intravenous injection, but was
rapidly cleared from other organs. By contrast, SIP(SP1)
and SIP(SP2), specific to MMP-1A and MMP-2, showed
no preferential accumulation at the tumour site.
Conclusion Antibodies specific to MMP-3 may serve as
vehicles for the efficient and selective delivery of imaging
agents or therapeutic molecules to sites of disease.
Keywords MMP-1A .MMP-2 .MMP-3 . Antibody .
Tumour targeting
Introduction
Monoclonal antibodies are increasingly being used for the
selective delivery of bioactive molecules (e.g. radionu-
clides, drugs, cytokines) to the site of disease, thus sparing
normal organs [1]. Although antibodies specific to mem-
brane antigens on cancer cells have mainly been used so far
for tumour-targeting applications, there is growing interest
in the use of stromal antigens and of markers of
angiogenesis as antibody targets [2], which have the
potential to offer broad tumour coverage and low expres-
sion in normal tissues.
Matrix metalloproteinases (MMPs) are a group of more
than 20 zinc-containing extracellular proteinases that are
capable of degrading multiple components of the extracel-
lular matrix. Abnormal expression of MMPs contributes to
a variety of pathological conditions. In the tumour
environment, for example, host- and tumour-derived MMPs
are often upregulated, while being expressed at low levels
in normal organs [3, 4]. Several studies of the use of MMPs
as targets for imaging purposes have been reported [5].
These approaches include the use of radiolabelled MMP
inhibitors as targeting agents, or the use of fluorogenic
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MMP-specific substrates combined with optical imaging
modalities. Since attempts to use radiolabelled MMP
inhibitors for in vivo tumour targeting applications have
often proved unsuccessful, possibly due to the limited
specificity of these agents or their unsuitable pharmacoki-
netic properties [5], radiolabelled monoclonal antibodies
could in principle be considered as an alternative.
We have previously reported on the isolation of three
high-affinity human monoclonal antibodies (termed SP1,
SP2 and SP3) specific to murine MMP-1A, MMP-2 and
MMP-3, respectively, using phage display technology.
These antibodies have been thoroughly characterized in
vitro and tested by immunofluorescence in a wide panel of
healthy and diseased tissues [4]. Here we describe the
cloning, production and characterization of these antibodies
in small immunoprotein (SIP) miniantibody format [6]
(Fig. 1a) and the comparative analysis of their tumour-
targeting properties in an allograft mouse model of cancer.
SIP(SP1) and SIP(SP2) showed no preferential accumula-
tion in the tumour. By contrast, both SIP(SP3) and SIP
(L19), a clinical stage recombinant antibody specific to the
alternatively spliced EDB domain of fibronectin (a marker
of tumour angiogenesis [2, 6]), exhibited selective accu-
mulation at the tumour site, as assessed by quantitative
biodistribution studies with radioiodinated antibody prepa-
rations. These results indicated that recombinant monoclo-
nal antibodies specific to MMP-3 may be used for imaging
purposes or for the selective delivery of bioactive moieties
to tumours or to disease areas where MMP-3 is known to
be overexpressed (e.g. in rheumatoid arthritis).
Material and methods
Cloning, expression, and purification of antibodies
in the SIP format
Single chain variable fragments (scFv) were converted into
the SIP format by cloning VH and VL into pcDNA3.1
(Invitrogen) using a previously described strategy [7, 8]
(Fig. 1a). The plasmids were transfected into CHO-S cells
(Invitrogen) using a Cell Line Nucleofector Kit V (Lonza),
following the manufacturer’s protocol. Transfectants were
grown in RPMI medium supplemented with 10% fetal calf
serum (FCS) and selected by addition of 0.5 mg/ml
Geneticin (G418) (Merck Chemicals). Monoclonal cultures
were obtained by fluorescent-activated cell sorting or by
limited dilution, as described previously [8]. After 10 to
14 days of selection, cells were suspended and cultured in
PowerCHO-2 CD medium (Lonza). SIP antibodies were
purified from culture medium by affinity chromatography
using a Protein A Sepharose Fast Flow resin (GE Health-
care), as described previously [8].
Characterization of the SIP antibodies
Purified SIP antibodies were analyzed by SDS-PAGE, size
exclusion chromatography on Superdex 200 HR10/300
columns (Amersham Biosciences) and by surface plasmon
resonance measurements on a low-density coated antigen
chip as described previously [7] to determine the apparent
KD.
Deglycosylation
To deglycosylate purified SIP(SP1), 15 µg protein samples
were incubated with 500 U PNGase F (New England
Biolabs) for 3 h at 37°C. The resulting product was
analysed directly by SDS-PAGE.
Immunofluorescence analysis/confocal laser scanning
microscopy of frozen tissue sections
F9 teratocarcinoma tissues were embedded in freezing
medium (Microm) and stored at −80°C until sectioned.
Tissue sections (10 µm) were fixed for 10 min with ice-cold
acetone, rehydrated with phosphate-buffered saline (PBS)
and blocked with 20% FCS in PBS. Biotinylated SIP(L19)
(2 µg/ml; specific to the alternatively spliced EDB domain
of fibronectin, used as positive control antibody of proven
tumour-targeting properties [6]), purified SIP(HyHEL-10)
(2 µg/ml; specific to hen egg lysozyme, used as negative
control antibody) or the purified antibodies scFv(SP1), scFv
(SP2) and scFv(SP3) (10–20 µg/ml) containing a myc-tag
were added onto the sections. As secondary reagents for the
scFvs a rat anti-myc antibody (Genetex) and for the SIP
(HyHEL-10) a rabbit anti-human-IgE (Dako) were applied.
The scFvs were detected using streptavidin Alexa Fluor 488
for SIP(L19), goat anti-rabbit IgG Alexa Fluor 488
(Invitrogen) for SIP(HyHEL-10) or donkey anti-rat IgG
Alexa Fluor 488 antibody (Invitrogen). Nuclei were
counterstained with DAPI (Invitrogen). All commercial
binding reagents were diluted according to the manufac-
turer’s recommendation. Sections were rinsed with PBS
between all incubation steps. Slides were mounted with
fluorescent mounting medium (Dako) and analysed using
Zeiss AxioVision 4.7 image analysis software (Carl Zeiss).
For laser scanning microscopy analysis all steps were
performed as described above. In addition, the cytoskeleton
was counterstained with Phalloidin-Alexa 647 (Invitrogen).
Slides were analysed using a LSM 510 META microscope
from Zeiss (Carl Zeiss).
Radioiodination of the SIP antibodies
Antibody radioiodination was performed as previously
described [7]. Briefly, 300 μg of protein was mixed with
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200 μCi of 125I (Perkin Elmer) and filtered aqueous
solution of chloramine T (Sigma) (5 mg/ml; 0.25 μg of
chloramine T per microgram of protein) for 1 min 45 s
followed by separation from unincorporated iodine using a
PD-10 disposable gel filtration column (GE Healthcare).
Antibody immunoreactivity after labelling was evaluated
by affinity chromatography as previously described [6].
Binding reactivity, defined as the ratio between the counts
of the eluted antibody and the sum of the counts (flow-
through, wash and eluate), was 79% for SIP(L19), 62% for
SIP(SP1), 67% for SIP(SP2), 84% for SIP(SP3) and 73%
for SIP(HyHEL-10).
Fig. 1 Antibodies against the catalytic domain of murine MMP-1A,
MMP-2 and MMP-3. a Schematic illustration of the scFv format
consisting of a heavy chain (VH) and a light chain (VL) linked by a
peptide linker, and a schematic illustration of the SIP format
consisting of a disulphide-linked homodimer. b SDS-PAGE analysis
of affinity-purified anti-MMP antibodies SIP(SP1), SIP(SP2) and SIP
(SP3) (m molecular weight marker, R SIP antibodies under reducing
conditions, NR SIP antibodies under nonreducing conditions). c Size
exclusion chromatogram of SIP(SP1), SIP(SP2) and SIP(SP3) on a
Superdex 200 HR10/300 column. The major peaks eluting at about
15 ml for SIP(SP1) and at about 16 ml for SIP(SP2) and SIP(SP3)
correspond to the molecular weight of the covalent homodimer. d
BIAcore sensograms of the antibodies SIP(SP1), SIP(SP2) and SIP
(SP3). Kinetic constants were calculated with the BIA evaluation 4.1
software
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Biodistribution of radiolabelled SIP antibodies in tumour-
bearing mice
F9 murine teratocarcinoma cells (2×107) were implanted
subcutaneously into the left flank of 10- to 12-week-old
129/SvEv mice (Taconic) and tumours were allowed to
grow for 8 days. The 125I-labelled antibody fragment (15–
20 µg; 3–6 µCi) in 100 µl saline solution, radiolabelled
immediately prior to use, was injected intravenously. Mice
were sacrificed 3 h, 24 h and 48 h after injection. Organs
were weighed and radioactivity was counted. Five to six
animals were used for each time point and each construct.
The radioactivity contents of representative organs are
expressed as the percentage of the injected dose per gram
of tissue (%ID/g) ±SE.
Biodistribution of radiolabelled SIP antibodies in healthy
mice
125I-labelled antibody fragments (30–40 µg; 3–6 µCi) in
200 µl saline solution, radiolabelled immediately prior to
use, were injected intravenously. Mice were sacrificed
30 min after injection. Urine was collected and was applied
to a disposable gel filtration column (GE Healthcare).
Fractions of 500 µl were collected and radioactivity was
measured. Organs were excised, weighed and the radioac-
tivity was counted. Two animals were used for each
construct. The radioactivity content of urine fractions is
expressed as counts per minute (cpm).
Murine blood serum analysis by surface plasmon resonance
Murine blood serum was analysed by surface plasmon
resonance on a BIAcore 3000 instrument (GE Healthcare),
using a high-density coated SIP antibody chip as described
previously [7]. A rabbit anti-human IgE antibody (Dako)
(final concentration 83 µg/ml) and buffered saline solution
were used as a positive control and as a negative control,
respectively.
The radioactivity content of representative organs is
expressed as the percentage of the injected dose per gram of
tissue (%ID/g).
Results
Production and characterization of antibodies SIP(SP1), SIP
(SP2) and SIP(SP3)
The human monoclonal antibody fragments scFv(SP1),
scFv(SP2) and scFv(SP3) were cloned in SIP format by
genetically fusing the scFv moiety at the N-terminal
extremity of a human εCH4 domain of the secretory
isoform S2 of human IgE [6] (Fig. 1a). This domain
promotes the formation of homodimers that are further
stabilized by disulphide bonds between the COOH terminal
cysteine residues, resulting in a 75-kDa bivalent minianti-
body (Fig. 1a). This format has previously been shown to
offer a good pharmacokinetic compromise between the
rapidly cleared scFv antibody fragments and the antibodies
in full IgG format, which display long circulatory half-lives
in vivo. Tumour-targeting SIPs typically show high tumour-
to-organ ratios at 24 h and at later time points after injection
[7].
SIP(SP1), SIP(SP2) and SIP(SP3) were expressed in
Chinese hamster ovary cells (CHO-S) from a pcDNA3.1-
based expression vector and purified by protein A affinity
chromatography of the cell culture supernatant. All three
recombinant antibodies quantitatively formed cysteine-
linked covalent homodimers, as shown by SDS-PAGE
under reducing and nonreducing conditions (Fig. 1b) and
by size-exclusion chromatography (Fig. 1c). SDS-PAGE of
SIP(SP1) revealed the presence of an N-glycosylation site,
which was confirmed by N-glycanase treatment (Supple-
mentary Fig. S1). The purified SIP(SP1), SIP(SP2) and SIP
(SP3) antibodies were also analysed by real-time interaction
analysis on a BIAcore instrument on a low-density micro-
sensor chip, which confirmed their high affinity to the
cognate antigens (Fig. 1d). The apparent KD values were
1.8 nM for SIP(SP1), 2.4 nM for SIP(SP2) and 1.9 nM for
SIP(SP3).
Biodistribution studies of SIP(SP1), SIP(SP2) and SIP(SP3)
in F9 tumour-bearing mice
The in vivo targeting performance of radioiodinated SIP
(SP1), SIP(SP2) and SIP(SP3) antibody preparations was
evaluated by biodistribution studies in mice bearing F9
teratocarcinoma. 125I-labelled SIP(L19), a clinical stage
recombinant antibody of proven tumour-targeting perfor-
mance [2, 6], was used as positive control. SIP(HyHEL-
10), an antibody specific to hen egg lysozyme, was used as
negative control. All three anti-MMP antibodies, as well as
L19, strongly stained F9 tumour sections as revealed by
immunofluorescence analysis, while HyHEL-10 did not
exhibit any detectable staining, as expected (Fig. 2a).
Confocal laser microscopy analysis revealed that MMP-
1A and MMP-3 were strongly expressed in the cytoplasm
and on the membrane of the F9 tumour cells, while MMP-2
was predominantly found in intracellular structures
(Supplementary Fig. S2). The antibodies were injected
intravenously. At different time points (3 h, 24 h, 48 h)
animals were sacrificed, organs were excised and weighed,
and the radioactivity was counted. The biodistribution
results are expressed as percent injected dose per gram of
tissue or body fluid (Table 1, Fig. 2b).
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The negative control antibody SIP(HyHEL-10) and the
antibodies SIP(SP1) and SIP(SP2), specific to MMP-1A
and MMP-2, respectively, were cleared very rapidly from
the bloodstream and from most normal organs and did not
show selective accumulation at the site of tumour (Table 1,
Fig. 2b). By contrast, both SIP(SP3), specific to MMP-3,
and SIP(L19) preferentially localized to the tumour (Table 1,
Fig. 2b).
The blood clearance profile of SIP(SP1) and SIP(SP2),
which both carry a VL domain consisting of the DPL-16
germline gene [4], was more rapid than that of SIP(L19)
and SIP(SP3), which carry a VL domain based on the DPK-
22 germline segment [4, 6]. All four antibodies contain a
VH domain based on the DP-47 germline gene [7] and are
identical in other portions of the SIP molecule. Comparison
of the biodistribution of three SIP antibodies based on
DPK-22 VL domains and five SIP antibodies based on
DPL-16 light chains revealed a general trend to faster blood
clearance for DPL-16-based antibodies (Supplementary
Fig. S3). The excretion of the SIP(SP2) antibody 30 min
after intravenous injection was more rapid than that of SIP
(SP3) and SIP(L19) (Supplementary Fig. S4a). While
Fig. 2 Immunofluorescence
analysis and biodistribution
studies after intravenous
injection of antibodies in F9
tumour-bearing mice. a Immu-
nofluorescence analysis was
performed on tumour cryosec-
tions. MMP-1A, MMP-2,
MMP-3 and extradomain B of
fibronectin are stained in green,
whereas cell nuclei were stained
in blue using DAPI (scale bar
100 µm). b Biodistribution of
125I-labelled SIP(SP1), SIP
(SP2), SIP(SP3) and of two
control antibodies SIP(L19) and
SIP(HyHEL-10) at 24 and 48 h.
Each value is the average from
five or six animals
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clearance via the hepatobiliary route predominates, anti-
body dehalogenation in the liver leads to the excretion of
free radioiodine through the kidneys, as revealed by a gel
filtration analysis of urine (Supplementary Fig. S4b). We
hypothesized that the longer retention of SIP(SP3) and SIP
(L19) in the blood could have been due to a noncovalent
association with serum components. Supplementary Fig. S5
reveals that indeed SIP(SP3), but not SIP(SP1) or SIP(SP2),
formed a complex with serum proteins, as revealed by real-
time interaction analysis on a BIAcore 3000 instrument.
Discussion
We have reported the first biodistribution analysis of the
tumour-targeting performance of three radiolabelled high-
affinity monoclonal antibodies, specific to three different
murine MMPs. While all three antibodies strongly stained
various tumour sections [4], including F9 tumours (Fig. 2a),
only the SIP(SP3) antibody, specific to murine MMP-3,
exhibited a preferential localization at the tumour site.
The biodistributions of the SP1, SP2, SP3 and L19
antibodies in SIP format were compared in mice bearing
murine tumours facilitated by the fact that the EDB
antigen has an identical sequence in mice and humans
[2], thus allowing characterization of tumour-targeting
properties in a syngeneic setting. To our knowledge, only
one biodistribution study with a monoclonal antibody
specific to membrane-bound human MMP-1 has previous-
ly been reported [9]. In that study, which involved a mouse
and a rat xenograft model, the antibody exhibited no
preferential localization to the tumour, which is in line with
our results.
Our recent immunohistochemical analysis of the patterns
of murine MMP-1A, MMP-2 and MMP-3 expression [4]
has shown that these antigens are undetectable in most
normal mouse tissues (except in the liver for MMP-2 and
MMP-3, and in the lung, brain and kidney for MMP-2), but
are strongly expressed in the majority of tumours tested,
making them suitable candidates for biomolecular antican-
cer pharmacodelivery strategies. In order to qualify for
antibody-based tumour-targeting applications, an antigen
needs to be accessible in vivo and also needs to mediate an
“immobilization” of the antibody on the neoplastic lesion.
The biodistribution results presented here indicate that
MMP-3 is sufficiently abundant and accessible in F9
tumours to permit a preferential antibody localization at
the neoplastic site. This protease is probably anchored to
extracellular matrix components via, for example, the NC1
domain of type IV collagen or the laminin-binding domain
of agrin, which are structurally similar to tissue inhibitors of
metalloproteinases (reviewed in reference [10]). MMP-1A
and MMP-3 showed a similar cellular localization in F9Ta
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tumour cells, but only MMP-3 could be efficiently targeted
in vivo. By contrast, in this tumour model, the majority of
MMP-2 was intracellular and thus not accessible to
antibodies in vivo (Supplementary Fig. S2).
Antibodies were used in SIP format for biodistribution
studies. Miniantibody formats have been extensively
studied by our group and in other laboratories, and appear
to provide an ideal compromise between the fast-clearing
scFv fragments and the long-lived IgGs [6]. Unlike scFv
and Fab fragments, antibodies in SIP format are mainly
cleared via the hepatobiliary route [6, 7], so that the kidneys
would be spared in radioimmunotherapy applications.
Indeed, 131I-labelled SIP(L19) and SIP(F16) are currently
being investigated in phase II radioimmunotherapy trials,
with a special focus on haematological malignancies [2],
and these two SIPs labelled with 124I are being studied in
immuno-PET clinical trials.
In line with previous observations in biodistribution
studies with antibodies in IgG, Fab and scFv formats, the
results presented in Table 1 show differences in blood
clearance properties among different SIPs, with the L19 and
SP3 antibodies being the longest-lived recombinant anti-
bodies in circulation. The reasons for these differences are
not obvious, since the cognate antigens are present at
negligibly low concentrations (nanograms per millilitre
levels or lower) in blood and since all antibodies have a
VH domain based on the same (DP-47) germline V
segment [4]. Interestingly, both SP3 and L19 carry a Vκ
domain based on the DPK-22 germline V segment, while
SP1 and SP2 have a Vλ domain, based on the DPL-16
germline segment. Biodistribution studies revealed that
DPL-16-based antibodies in SIP format clear more rapidly
from the blood than antibodies containing DPK-22 light
chains (Supplementary Fig. S3). A previously unsuspected
noncovalent binding interaction of SP3 with serum, clearly
revealed by BIAcore analysis (Supplementary Fig. S5),
may account for the longer residence time of this antibody
in the bloodstream (Fig. 2b, Table 1). Both L19 and SP3
exhibited a long residence time on the tumour in vivo, a
favourable property for the use of these antibodies as
building blocks for the development of targeted anticancer
biopharmaceuticals.
The selective tumour localization properties of SIP(SP3)
suggest that anti-MMP-3 antibodies may be useful for the
immuno-PET visualization of this antigen in patients with
cancer, but also in other pathologies where MMP-3 is
strongly overexpressed (e.g. rheumatoid arthritis). In
addition to nuclear medicine applications, it would be
conceivable to use anti-MMP-3 antibodies for pharmaco-
delivery applications, in full analogy with antibodies
specific to splice isoforms of fibronectin and tenascin-C
[2, 6, 7], which have been fused to cytokines, photo-
sensitizers, procoagulant factors, enzymes and drugs. Some
of these derivatives (most notably L19-IL2, L19-TNF, F16-
IL2, F8-IL10) are currently being investigated in clinical
trials. However, since the catalytic domain of MMP-3
displays only an 82% homology between mouse and man,
human-specific monoclonal antibodies will be needed for
clinical applications.
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